Billionaire hedge-fund manager Bill Ackman’s largest-ever “blank check” company went public Wednesday, with more than $4 billion in its kitty to acquire a yet-undetermined company, and it has two years to pick one.
U.S. stocks were mostly higher Wednesday, ahead of corporate results from Tesla and Microsoft, but with buying seen in utilities and other sectors viewed as defensive, as Sino-American tensions rise.
Gold and silver rise further Wednesday, getting a boost after China said the U.S. had ordered it to close its Houston consulate, marking a further climb in tensions between the two countries and sparking demand for haven assets.
‘As the massive monetary and massive fiscal stimuli (over $15T globally) conjoin to save the economy from a deflationary depression, they will cause instead a hyperinflationary economic collapse,’ Larry McDonald warned.
Earlier this year, lBill Smead expressed his frustrations over Warren Buffett’s “maximum defense” approach. A couple months later and he’s still taking issue with the Berkshire boss.
Morgan Stanley will start measuring and disclosing lending portfolio greenhouse gas emissions and back the push toward universal climate-risk accounting — the first U.S. bank to take such actions.
A Republican senator who had publicly held off endorsing Federal Reserve Board nominee Judy Shelton said Monday he would support her, likely clearing the way to floor vote soon
The Montreal Cognitive Assessment, or MoCA, test discussed by President Trump and Chris Wallace is ‘not an IQ test,’ Dr. Ziad Nasreddine tells MarketWatch
International Business Machines Corp. shares gained in after-hours trading Monday, after the tech giant reported another decline in revenue but produced more profit and sales than Wall Street expected amid the COVID-19 pandemic.
European stocks traded cautiously lower on Monday, as top leaders still are negotiating on a rescue fund to bolster the economic response to the coronavirus.
GlaxoSmithKline on Monday said it was taking a stake in German vaccines maker CureVac, the latest move by a major drugmaker to boost capabilities to fight pandemics.